Publicaciones en colaboración con investigadores/as de Harvard Medical School (19)

2023

  1. The International Consensus Classification of myelodysplastic syndromes and related entities

    Virchows Archiv, Vol. 482, Núm. 1, pp. 39-51

2022

  1. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950

  2. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6

  3. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1

  4. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024

2021

  1. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 6, pp. 2139-2144

  2. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 5, pp. 2083-2086

  3. GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness

    Blood, Vol. 138, Núm. 17, pp. 1590-1602

  4. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  5. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference

    Journal of Allergy and Clinical Immunology

  6. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 11, pp. 3918-3928

  7. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

    HemaSphere, Vol. 5, Núm. 11, pp. E646

2020

  1. Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts

    Theranostics, Vol. 10, Núm. 23, pp. 10743-10768

  2. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions

    Journal of Allergy and Clinical Immunology, Vol. 146, Núm. 2, pp. 300-306

2018

  1. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis

    Blood Advances, Vol. 2, Núm. 18, pp. 2400-2411

2017

  1. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

    Oncotarget, Vol. 8, Núm. 43, pp. 73483-73500

2015

  1. A global reference for human genetic variation

    Nature, Vol. 526, Núm. 7571, pp. 68-74

2014

  1. Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel

    Nature Communications, Vol. 5

2012

  1. An integrated map of genetic variation from 1,092 human genomes

    Nature, Vol. 491, Núm. 7422, pp. 56-65